Patent ductus arteriosus

Common Name(s)

Patent ductus arteriosus

Persistent patency of the ductus arteriosus, or patent ductus arteriosus (PDA), is the second most common congenital heart disease, affecting approximately 1 in 1,600 to 5,000 live births in the U.S. ({3:Mitchell et al., 1971}). In fetal life, the ductus arteriosus, a muscular artery, shunts blood from the pulmonary artery to the aorta, bypassing the lungs. Its abrupt closure at birth establishes the mature circulatory pattern and represents a dramatic example of vascular remodeling. Failure of this normal process results in persistent PDA, which left untreated can result in pulmonary hypertension and heart failure. Closure of the ductus is a complex process. Aspects of this process are regulated by oxygen tension and a decrease in levels of hormones such as prostaglandin E2. PDA occurring in preterm infants often closes spontaneously or in response to inhibitors of prostaglandin biosynthesis ({6:Ramsay et al., 1987}). Term PDA typically has not been regarded as a genetic disorder, because it most often occurs sporadically. Nonetheless, term PDA recurs among 5% of sibs of PDA cases ({5:Polani and Campbell, 1960}; {1:Lamy et al., 1957}), suggesting a genetic component to disease pathogenesis that has typically been presumed to be multifactorial. That single genes can influence this trait has been demonstrated by a mouse model of PDA resulting from disruption of the prostaglandin E2 receptor ({4:Nguyen et al., 1997}) and by rare syndromic forms of PDA such as Char syndrome ({169100}), an autosomal dominant disorder caused by mutations in the transcription factor TFAP2B ({601601}) ({2:Mani et al., 2002}).
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Patent ductus arteriosus" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Patent ductus arteriosus" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Patent ductus arteriosus" returned 312 free, full-text research articles on human participants. First 3 results:

Safety of percutaneous patent ductus arteriosus closure: an unselected multicenter population experience.
 

Author(s): Howaida G El-Said, Andras Bratincsak, Susan R Foerster, Joshua J Murphy, Julie Vincent, Ralf Holzer, Diego Porras, John Moore, Lisa Bergersen

Journal:

 

The technique and safety of transcatheter patent ductus arteriosus (PDA) closure have evolved during the past 20 years. We sought to report a multicenter experience of PDA closure with a focus on the rate of adverse events (AE) and a review of institutional practice differences.

Last Updated: 28 Nov 2013

Go To URL
Comparison of transvenous versus transthoracic catheter-based device closure of patent ductus arteriosus with amplatzer duct occluder.
 

Author(s): Lin-Yan Chen, Ping Cai, Zhen-Dong Cheng, Zai-Bao Zhang, Dao-Zhong Chen, Hua Cao, Han-Fan Qiu, Liang-Long Chen

Journal: J Invasive Cardiol. 2013 Oct;25(10):502-6.

 

This study compared the clinical outcome of the transvenous versus transthoracic approach for closure of patent ductus arteriosus (PDA).

Last Updated: 3 Oct 2013

Go To URL
Patent ductus arteriosus with pulmonary endarteritis.
 

Author(s): Yukiharu Sugimura, Masanori Katoh, Masaaki Toyama

Journal: Intern. Med.. 2013 ;52(18):2157-8.

 

Last Updated: 17 Sep 2013

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Patent ductus arteriosus" returned 27 free, full-text review articles on human participants. First 3 results:

The role of patent ductus arteriosus and its treatments in the development of bronchopulmonary dysplasia.
 

Author(s): Ronald I Clyman

Journal: Semin. Perinatol.. 2013 Apr;37(2):102-7.

 

A persistent left-to-right shunt through a patent ductus arteriosus (PDA) increases the rate of hydrostatic fluid filtration into the lung's interstitium, impairs pulmonary mechanics, and prolongs the need for mechanical ventilation. In preclinical trials, pharmacologic PDA closure ...

Last Updated: 15 Apr 2013

Go To URL
Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all?
 

Author(s): Ronald I Clyman, James Couto, Gail M Murphy

Journal: Semin. Perinatol.. 2012 Apr;36(2):123-9.

 

Although a moderate-sized patent ductus arteriosus (PDA) needs to be closed by the time a child is 1-2 years old, there is great uncertainty about whether it needs to be closed during the neonatal period. Although 95% of neonatologists believe that a moderate-sized PDA should be closed ...

Last Updated: 14 Mar 2012

Go To URL
Should we definitively abandon prophylaxis for patent ductus arteriosus in preterm new-borns?
 

Author(s): Vassilios Fanos, Michele Pusceddu, Angelica Dessì, Maria Antonietta Marcialis

Journal: Clinics (Sao Paulo). 2011 ;66(12):2141-9.

 

Although the prophylactic administration of indomethacin in extremely low-birth weight infants reduces the frequency of patent ductus arteriosus and severe intraventricular hemorrhage, it does not appear to provide any long-term benefit in terms of survival without neurosensory and ...

Last Updated: 22 Dec 2011

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus
 

Status: Recruiting

Condition Summary: Patent Ductus Arteriosus; Surgery; Necrotizing Enterocolitis; Intestinal Perforation

 

Last Updated: 8 Jul 2014

Go to URL
Influence of Treatment for Patent Ductus Arteriosus on Cerebral Oxygenation in Preterm Infants
 

Status: Recruiting

Condition Summary: Prematurity of Fetus; Patent Ductus Arteriosus

 

Last Updated: 24 Jul 2012

Go to URL
Treating the Resistant Patent Ductus Arteriosus (PDA)
 

Status: Not yet recruiting

Condition Summary: Patent Ductus Arteriosus

 

Last Updated: 14 Feb 2008

Go to URL